Literature DB >> 21346147

Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis.

Wei Kang1, Joanna H M Tong, Anthony W H Chan, Tin-Lap Lee, Raymond W M Lung, Patrick P S Leung, Ken K Y So, Kaichun Wu, Daiming Fan, Jun Yu, Joseph J Y Sung, Ka-Fai To.   

Abstract

PURPOSE: Yes-associated protein 1 (YAP1) is a multifunctional protein that can interact with different transcription factors to activate gene expression. The role of YAP1 in tumorigenesis is unclear. We aimed to investigate the functional role of YAP1 in tumorigenesis of gastric cancer. EXPERIMENTAL
DESIGN: YAP1 expression in gastric adenocarcinoma was evaluated. The biological function was determined by proliferation assay, colony formation, cell invasion, and flow cytometric analysis through knocking down or ectopic expressing YAP1 in gastric cancer cell lines coupled with in vivo study. The possible downstream effectors of YAP1 were investigated by expression microarray.
RESULTS: YAP1 protein expression was upregulated in gastric cancer. Nuclear accumulation of YAP1 was associated with poor disease-specific survival (P = 0.021), especially in patients with early-stage diseases (P < 0.001). Knockdown YAP1 resulted in a significant reduction in proliferation, anchorage-dependent colony formation, cell invasion, and cell motility. Ectopic YAP1 expression promoted anchorage-independent colony formation, induced a more invasive phenotype, and accelerated cell growth both in vitro and in vivo. Microarray analysis highlighted the alteration of MAPK (mitogen-activated protein kinase) pathway by YAP1. We confirmed a constitutive activation of RAF/MEK/ERK (extracellular signal-regulated kinase) in YAP1-expressing MKN45 cells and further showed that YAP1 enhanced serum/epidermal growth factor-induced c-Fos expression in gastric cancer cells.
CONCLUSIONS: Our findings supported that YAP1 exhibits oncogenic property in gastric cancer. We provided the first evidence that YAP1 exerted the oncogenic function by enhancing the capacity to activate the early-response gene pathway. YAP1 could be a prognostic biomarker and potential therapeutic target for gastric cancer. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346147     DOI: 10.1158/1078-0432.CCR-10-2467

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  128 in total

1.  Wnt2 promotes non-small cell lung cancer progression by activating WNT/β-catenin pathway.

Authors:  Chongbiao Huang; Ruijue Ma; Yong Xu; Na Li; Zengxun Li; Jie Yue; Haixin Li; Yan Guo; Daliang Qi
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

2.  Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor.

Authors:  Andrew J Murphy; Janene Pierce; Christian de Caestecker; Jaime Libes; David Neblett; Mark de Caestecker; Alan O Perantoni; Shunsuke Tanigawa; James R Anderson; Jeffrey S Dome; Amrita Das; Thomas J Carroll; Harold N Lovvorn
Journal:  Pediatr Blood Cancer       Date:  2013-09-20       Impact factor: 3.167

3.  Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties.

Authors:  Shumei Song; Jaffer A Ajani; Soichiro Honjo; Dipen M Maru; Qiongrong Chen; Ailing W Scott; Todd R Heallen; Lianchun Xiao; Wayne L Hofstetter; Brian Weston; Jeffrey H Lee; Roopma Wadhwa; Kazuki Sudo; John R Stroehlein; James F Martin; Mien-Chie Hung; Randy L Johnson
Journal:  Cancer Res       Date:  2014-06-06       Impact factor: 12.701

Review 4.  Hippo-YAP signaling in digestive system tumors.

Authors:  Feng Yin; Jixin Dong; Liang-I Kang; Xiuli Liu
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

5.  Matrix stiffness epigenetically regulates the oncogenic activation of the Yes-associated protein in gastric cancer.

Authors:  Minjeong Jang; Jinhyeon An; Seung Won Oh; Joo Yeon Lim; Joon Kim; Jung Kyoon Choi; Jae-Ho Cheong; Pilnam Kim
Journal:  Nat Biomed Eng       Date:  2020-12-07       Impact factor: 25.671

6.  A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma.

Authors:  Shumei Song; Min Xie; Ailing W Scott; Jiankang Jin; Lang Ma; Xiaochuan Dong; Heath D Skinner; Randy L Johnson; Sheng Ding; Jaffer A Ajani
Journal:  Mol Cancer Ther       Date:  2017-11-22       Impact factor: 6.261

7.  Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice.

Authors:  Miki Nishio; Koichi Hamada; Kohichi Kawahara; Masato Sasaki; Fumihito Noguchi; Shuhei Chiba; Kensaku Mizuno; Satoshi O Suzuki; Youyi Dong; Masaaki Tokuda; Takumi Morikawa; Hiroki Hikasa; Jonathan Eggenschwiler; Norikazu Yabuta; Hiroshi Nojima; Kentaro Nakagawa; Yutaka Hata; Hiroshi Nishina; Koshi Mimori; Masaki Mori; Takehiko Sasaki; Tak W Mak; Toru Nakano; Satoshi Itami; Akira Suzuki
Journal:  J Clin Invest       Date:  2012-11-12       Impact factor: 14.808

8.  RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription.

Authors:  Jianjun Wang; Feng Huang; Yaxiang Shi; Qinghui Zhang; Song Xu; Yongliang Yao; Runqiu Jiang
Journal:  Gastric Cancer       Date:  2020-07-04       Impact factor: 7.370

9.  Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.

Authors:  Weiying Zhang; Nivedita Nandakumar; Yuhao Shi; Mark Manzano; Alias Smith; Garrett Graham; Swati Gupta; Eveline E Vietsch; Sean Z Laughlin; Mandheer Wadhwa; Mahandranauth Chetram; Mrinmayi Joshi; Fen Wang; Bhaskar Kallakury; Jeffrey Toretsky; Anton Wellstein; Chunling Yi
Journal:  Sci Signal       Date:  2014-05-06       Impact factor: 8.192

10.  Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.

Authors:  Hao Wu; Yan Liu; Xiao-Wei Jiang; Wen-Fang Li; Gang Guo; Jian-Ping Gong; Xiong Ding
Journal:  Tumour Biol       Date:  2016-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.